Enfusion, Clearwater

Clearwater agrees to buy investment management platform Enfusion for $1.5B
Clearwater Analytics said it has entered into a definitive agreement to acquire investment management platform Enfusion for $1.5 billion.
Clearwater acquires Enfusion in $1.5B financial software deal
Clearwater Analytics Holdings Inc. today announced plans to acquire Enfusion Inc., a fellow provider of financial software, for $1.5 billion in cash and stock.
Clearwater Analytics to buy software maker Enfusion for $1.5 billion to drive global expansion
Clearwater Analytics has agreed to acquire Enfusion in a $1.5 billion cash-and-stock deal as the financial software maker looks to bolster its international presence and enter the hedge fund industry.
Clearwater Analytics to buy Enfusion for $11.25 a share
Clearwater Analytics to acquire Enfusion for $1.5 billion in a cash and stock deal, expanding into hedge fund industry with anticipated growth.
Clearwater to acquire Enfusion to expand its Investment Management Platform
IBS Intelligence (IBSi) is the world’s only pure-play Financial Technology focused research, advisory, and fintech news analysis firm, with a 30-year track record and clients globally. We take pride in covering 400+ technology vendors globally – the largest by any analyst firm in this space.
Clearwater Analytics to Acquire Enfusion in $1.5 Billion Deal
(Reuters) -Clearwater Analytics has agreed to acquire investment management platform Enfusion in a $1.5 billion cash-and-stock deal, the companies said on Monday. Enfusion shareholders will receive $5.85 in cash and $5.40 in Clearwater stock for each share, valuing the company at $11.25 per share, a 13% premium to its last close.
Clearwater Analytics upgraded to Buy at DA Davidson on ‘strategic’ Enfusion deal
DA Davidson upgraded Clearwater Analytics (CWAN) to Buy from Neutral with a price target of $32, down from $35. The company’s proposed merger
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Enfusion, Inc. (ENFN) And Encourages Investors to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / January 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between ...
Enfusion (NYSE:ENFN) Given “Market Perform” Rating at William Blair
Enfusion (NYSE:ENFN – Get Free Report)‘s stock had its “market perform” rating reaffirmed by equities research analysts at ...
Business Wire2d
ENFUSION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of En…
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are ...
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Enfusion Inc For Securities Fraud
LOS ANGELES, CA / ACCESS Newswire / January 16, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...
Enfusion downgraded to Hold from Buy at Stifel
Stifel analyst J. Parker Lane downgraded Enfusion (ENFN) to Hold from Buy with a price target of $11.25, down from $13, after the company announced an agreement to be acquired by Clearwater Analytics ...
Clearwater Analytics acquires software maker Enfusion for $1.5 billion to drive global expansion
Clearwater Analytics has agreed to acquire rival Enfusion in a $1.5 billion cash-and-stock deal as the financial software ...
Enfusion downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Michael Infante downgraded Enfusion (ENFN) to Equal Weight from Overweight with a price target of $11.25, up from $11.
Worth Playing1d
'Arma Reforger' Launches $100,000 Make Arma Not War 2025 Modding Competition - Trailer
Experience authentic Cold War combat and join friends in the struggle for a sprawling, 51 km² mid-Atlantic island — or take on the role of Game Master and create your very own scenarios for others to ...